RT Journal Article
SR Electronic
T1 Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.08.20054551
DO 10.1101/2020.04.08.20054551
A1 Lane, Jennifer C.E.
A1 Weaver, James
A1 Kostka, Kristin
A1 Duarte-Salles, Talita
A1 Abrahao, Maria Tereza F.
A1 Alghoul, Heba
A1 Alser, Osaid
A1 Alshammari, Thamir M
A1 Biedermann, Patricia
A1 Burn, Edward
A1 Casajust, Paula
A1 Conover, Mitch
A1 Culhane, Aedin C.
A1 Davydov, Alexander
A1 DuVall, Scott L.
A1 Dymshyts, Dmitry
A1 Fernandez-Bertolin, Sergio
A1 Fišter, Kristina
A1 Hardin, Jill
A1 Hester, Laura
A1 Hripcsak, George
A1 Kent, Seamus
A1 Khosla, Sajan
A1 Kolovos, Spyros
A1 Lambert, Christophe G.
A1 van der Lei, Johan
A1 Lynch, Kristine E.
A1 Makadia, Rupa
A1 Margulis, Andrea V.
A1 Matheny, Michael E.
A1 Mehta, Paras
A1 Morales, Daniel R.
A1 Morgan-Stewart, Henry
A1 Mosseveld, Mees
A1 Newby, Danielle
A1 Nyberg, Fredrik
A1 Ostropolets, Anna
A1 Park, Rae Woong
A1 Prats-Uribe, Albert
A1 Rao, Gowtham A.
A1 Reich, Christian
A1 Reps, Jenna
A1 Rijnbeek, Peter
A1 Sathappan, Selva Muthu Kumaran
A1 Schuemie, Martijn
A1 Seager, Sarah
A1 Sena, Anthony
A1 Shoaibi, Azza
A1 Spotnitz, Matthew
A1 Suchard, Marc A.
A1 Swerdel, Joel
A1 Torre, Carmen O.
A1 Vizcaya, David
A1 Wen, Haini
A1 de Wilde, Marcel
A1 You, Seng Chan
A1 Zhang, Lin
A1 Zhuk, Oleg
A1 Ryan, Patrick
A1 Prieto-Alhambra, Daniel
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/31/2020.04.08.20054551.abstract
AB Background Hydroxychloroquine has recently received Emergency Use Authorization by the FDA and is currently prescribed in combination with azithromycin for COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin.Methods New user cohort studies were conducted including 16 severe adverse events (SAEs). Rheumatoid arthritis patients aged 18+ and initiating hydroxychloroquine were compared to those initiating sulfasalazine and followed up over 30 days. Self-controlled case series (SCCS) were conducted to further establish safety in wider populations. Separately, SAEs associated with hydroxychloroquine-azithromycin (compared to hydroxychloroquine-amoxicillin) were studied. Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, Netherlands, Spain, UK, and USA. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate calibrated hazard ratios (CalHRs) according to drug use. Estimates were pooled where I2<40%.Results Overall, 956,374 and 310,350 users of hydroxychloroquine and sulfasalazine, and 323,122 and 351,956 users of hydroxychloroquine-azithromycin and hydroxychloroquine-amoxicillin were included. No excess risk of SAEs was identified when 30-day hydroxychloroquine and sulfasalazine use were compared. SCCS confirmed these findings. However, when azithromycin was added to hydroxychloroquine, we observed an increased risk of 30-day cardiovascular mortality (CalHR2.19 [1.22-3.94]), chest pain/angina (CalHR 1.15 [95% CI 1.05-1.26]), and heart failure (CalHR 1.22 [95% CI 1.02-1.45])Conclusions Short-term hydroxychloroquine treatment is safe, but addition of azithromycin may induce heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length. We call for caution if such combination is to be used in the management of Covid-19.Trial registration number Registered with EU PAS; Reference number EUPAS34497 (http://www.encepp.eu/encepp/viewResource.htm?id=34498). The full study protocol and analysis source code can be found at https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine.Funding sources This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and Senior Research Fellowship (DPA), US National Institutes of Health, Janssen Research & Development, IQVIA, and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. Personal funding included Versus Arthritis [21605] (JL), MRC-DTP [MR/K501256/1] (JL), MRC and FAME (APU). The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, NHS or the Department of Health, England.Competing Interest Statementall authors have completed an ICJME formClinical TrialRegistered with EU PAS; Reference number EUPAS34497 (http://www.encepp.eu/encepp/viewResource.htm?id=34498). The full study protocol and analysis source code can be found at https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine.Clinical Protocols http://www.encepp.eu/encepp/viewResource.htm?id=34498 https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine. Funding StatementThis research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and Senior Research Fellowship (DPA), US National Institutes of Health, Janssen Research & Development, IQVIA, and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. Personal funding included Versus Arthritis [21605] (JL), MRC-DTP [MR/K501256/1] (JL), MRC and FAME (APU). The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, NHS or the Department of Health, England.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study was conducted as a distributed database network analysis. To protect patient privacy, all patient-level data were maintained securely behind institutional firewalls. Analysis code was downloaded and executed by each participating data partner, which generated only aggregate summary statistics (cohort counts, model coefficients) which were then centralized and synthesized in preparation of this manuscript. All aggregate summary statistics produced have been made publicly available at: https://data.ohdsi.org/Covid19EstimationHydroxychloroquine/. https://data.ohdsi.org/Covid19EstimationHydroxychloroquine/ https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine https://github.com/ohdsi-studies/Covid19DrugRepurposing